EUCTR2012-004125-24-GB进行中（未招募）不适用
A prospective randomized Phase III trial of carboplatin/gemcitabing/bevacizumab vs caboplatin/pegylated lipsomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer - OPSROC (AGO-OVAR 2.21 / ENGOT-ov 18)
Greater Glasgow Health Board0 个研究点目标入组 654 人开始时间: 2014年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 654
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •(1) Written informed consent
- •(2) Females >= 18 years
- •(3) Histologically confirmed diagnosis of:
- •- epithelial ovarian carcinoma (including mixed Mullerian tumours) or
- •- fallopian tube carcinoma or
- •- primary peritoneal carcinoma
- •All FIGO stages, histological grades and types are allowed
- •(4) First disease recurrence > 6 months after first-line platinum-based chemotherapy, no prior chemotherapy in the recurrent setting is allowed.
- •(5) Patient with measurable or non-measurable disease (according to RECIST v1.1) or CA125 assessable disease (according to GCIG criteria) or histological proven diagnosis or relapse
- •(6) In case of cytoreductive surgery for recurrent, patients must be able to commence cytotoxic chemotherapy within 8 weeks after cytoreductive surgery. The first dose of bevacizumab can be omitted in both arms if the investigator decides to start chemotherapy within 4 weeks after debulking surgery for recurrent disease.
- •(7) ECOG performance status (PS) 0-2
- •(8) Life expectancy > 3 months
- •(9) Adequate bone marrow function (within 28 days prior to randomisation):
- •- ANC >= 1.5 x 109
- •- Platelets >= 100 x 109
- •- Haemoglobin >= 9.5 g/dL
- •(10) Adequate coagulation parameters (within 28 days prior to randomisation:
- •- Patients not receiving anticoagulant medication who have an INR <=1.5 and an aPTT <= 1.5 x ULN
- •(11) Adequate liver function (within 28 days prior to randomisation):
- •- serum bilirubin (BR) <= 2 x ULN
- •- serum transaminases <= 2.5 x ULN (<= 5 x ULN in the presence of liver metastasis)
- •(12) Adequate renal function (within 28 days prior to randomisation):
- •- serum creatinine < 1.6 mg/dL or creatiine clearance >= 40 mL/min
- •- Glomerular filtration rate > 40 ml/min based on the Cockcroft-Gault or Jelliffe formula are sufficient)
- •- Urine dipstick for proteinuria < 2+
- •(13) Normal blood pressure or adequately treatment and controlled hypertension (systolic BP <= 140mmHg and/or diastolic BP <= 90mmHg)
- •Please see protocol for full details on inclusion criteria.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •(1) Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tumors).
- •(2) Ovarian tumors of low malignant potential (i.e. borderline tumors)
- •(3) Malignancies other than ovarian cancer within 5 years prior to randomisation, except for adequately treated:
- •- carcinoma in situ of the cervix
- •- and/or basal cell skin cancer
- •- and/or non-melanomatous skin cancer
- •- and/or carcinoma in situ of the breast
- •- and/or endometrial carcinoma (FIGO stage <= 1A)
- •Patients may have received previous adjuvant chemotherapy for other malignancies e.g. breast or colorectal carcinoma if diagnosed over 5 years ago before randomisation with no evidence of subsequent recurrence
- •(4) Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormone replacement therapy is permitted as are steroidal antiemetics)
- •(5) Any previous radiotherapy to the abdomen or pelvis
- •(6) Treatment with any other investigational agent, or participation in another clinical trial testing a drug within the past 30 days before randomisation
- •(7) Known hypersensitivity to used chemotherapeutic agents in this trial and bevacizumab and its excipients, chinese hamster ovary cell products or other recombinant hum or humanised antibodies
- •(8) Current or recent (within 10 days prior to randomisation) chronic use of aspirin >325 mg/day
- •(9) Surgery (including open biopsy) within 4 weeks prior to anticipated first dose of bevacizumab (allowed for the fact that bevacizumab can be omitted for the first cycle of chemotherapy). It is strongly recommended that an interval of 7 days is left between the insertion of any central venous access devices (CVADs) and the onset of bevacizumab treatment.
- •(10) Any planned surgery during the treatment period plus 4 additional weeks to allow for bevacizumab clearance
- •(11) History of VEGF therapy related abdominal fistula or gastrointestinal perforation
- •(12) Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease
- •(13) Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure
- •(14) Previous Cerebro-Vascular Accident (CVA), Transient Ischaemic Attack (TIA) or Sub-Arachnoid Haemorrhage (SAH) within 6 months prior to randomisation
- •(15) Prior history of hypertensive crisis or hypertensive encephalopathy. Uncontrolled hypertension (sustained elevation of systolic blood pressure > 140 mmHg and/or diastolic >90 mmHg despite antihypertensive therapy).
- •(16) Clinically significant (i.e. active) cardiovascular disease, including:
- •- myocardial infarction or unstable anginal within <= 6 months of randomisation
- •- New York Heart Association (NYHA) >=grade 2 Congestive Heart Failure (CHF)
- •- poorly controlled cardiac arrhythmia despite medication (patients with rate-controlled atrial fibrillation are eligible)
- •- peripheral vascular disease grade >= 3 (i.e. symptomatic and interfering with activities of daily living (ADL) requiring repair or revision)
- •(17) Left ventricular ejection fraction (LVEF) defined by ECHO/MUGA below the institutional lower limit of normal
- •(18) Significant traumatic injury during 4 weeks prior to randomisation
- •(19) Current brain metastases or spinal cord compression. CT/MRI of the brain is mandatory (within 4 weeks prior to randomisation) in case of sus
研究者
相似试验
已完成
3 期
A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.MedDRA - 10016180 (Fallopian tube cancer)MedDRA - 10066697 (Ovarian cancer recurrent)C56C57Malignant neoplasm of ovaryMalignant neoplasm of other and unspecified female genital organsDRKS00004913AGO Research GmbH, AGO Study Group682
进行中（未招募）
不适用
Evaluation of optimal treatment combination of bevacizumab in combination with gemcitabine/carboplatin or pegylated liposomal doxorubicin/carboplatin in patients with platin-sensitive recurrent ovarian cancer.Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.MedDRA version: 18.1Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004125-24-BEAGO Research GmbH654
进行中（未招募）
1 期
Evaluation of optimal treatment combination of bevacizumab in combination with gemcitabine/carboplatin or pegylated liposomal doxorubicin/carboplatin in patients with platin-sensitive recurrent ovarian cancer.EUCTR2012-004125-24-DEAGO Research GmbH654
进行中（未招募）
1 期
Evaluation of optimal treatment combination of bevacizumab in combination with gemcitabine/carboplatin or pegylated liposomal doxorubicin/carboplatin in patients with platin-sensitive recurrent ovarian cancer.Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.MedDRA version: 18.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-004125-24-ATAGO Research GmbH654
进行中（未招募）
1 期
A Phase 3, Open, Randomized controlled trial on Completion Rate of daily Rifapentine/Isoniazid for One Month Compared with Daily Rifampicin/Isoniazid for Three Months for the Treatment of Latent Tuberculosis Infection among asylum seekers and refugeeslatent tuberculosis infectionMedDRA version: 20.0Level: PTClassification code 10065048Term: Latent tuberculosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-002063-95-ITAZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA238